Cullinan Therapeutics (NASDAQ:CGEM) expects 2026 to be a catalyst-heavy year across its pipeline, led by two “high-priority” T-cell engager programs in autoimmune disease and acute myeloid leukemia ...

Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for ...

Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

With sales of Immunocore’s melanoma medicine steadily ticking up and an expanded label likely down the line, CEO Bahija ...

Accessibility remains one of the largest barriers to translating academic best practices into a community oncology setting, according to several panelists at the Boston Regional Institute for ...

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...

Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19, ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...